Overall survival in patients with acute lymphoblastic leukemia treated with CALGB 8811 protocol in low income country


  • Livia Andrade Gurgel
  • Deivide de sousa Oliveira
  • João Paulo Vasconcelos Leitão
  • Karine Sampaio Nunes Barroso
  • Beatriz Stella Gomes de Souza Pitombeira
  • Isabella Araujo Duarte
  • João Vitor Araujo Duarte
  • Beatrice Araujo Duarte
  • Fernando Barroso Duarte




Precursor Cell Lymphoblastic Leukemia-Lymphoma, Stem Cell Transplantation, CALGB8811 protocol


Introduction: ALL is known to have a lower survival rate in adults and this can be attributed, among other aspects, to intolerance to intensive regimens. As the treatment of ALL is very complex, with many protocols available, this study proposes an analysis regarding the CALGB 8811 protocol in a tertiary health unit in Ceará

Methods: In this retrospective study, 50 patients with a recent diagnosis of ALL who underwent the CALGB8811 protocol were evaluated. Disease risk criteria were based on the CALGB8811 protocol.

Results: CR was obtained in 86% of patients. 12% of patients died during induction due to infectious complications. 30% of patients underwent alloSCT, 60% were on CR1.

The median overall survival (OS) was 21.5 months (8.1-38.7). The 5 years OS was 25% in the transplanted patients versus 60% in the transplanted group. Achieving complete remission after induction chemotherapy and allogeneic hematopoietic stem cell transplantation were the factors associated with better long-term survival rates in uni and multivariate analysis.

Conclusion: Risk factors classically associated with worse adult ALL outcome and post-induction MRD status were not outcome predictors, in addition, post-induction remission and alloSCT were factors associated with a favorable outcome.




How to Cite

Gurgel, L. A., Oliveira, D. de sousa, Leitão, J. P. V., Barroso, K. S. N., Pitombeira, B. S. G. de S., Duarte, I. A., Duarte, J. V. A., Duarte, B. A., & Duarte, F. B. (2021). Overall survival in patients with acute lymphoblastic leukemia treated with CALGB 8811 protocol in low income country. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 2(2), p95. https://doi.org/10.46765/2675-374X.2021v2n2p95

Most read articles by the same author(s)

1 2 > >>